Resolve Biosciences raises $71 million

With its technology, the science start-up was able to convince the investors Patient Square Capital and EDBI.

In a Series B financing round, the start-up Resolve Biosciences from Monheim am Rhein, Germany, raised $71 million. Patient Square Capital led the round. EDBI, PS Capital, Alafi Capital and NRW-Bank also participated. Existing investors also invested again. According to the company, Resolve Biosciences has now received a total of more than $100 million.

"This Series B funding is another strong validation of our mission, our technology and our team," said co-founder and CEO Jason T. Gammack. The company, founded in 2020, uses so-called molecular mapping to enable scientists to make new discoveries based on a high-resolution view of the spatial biology of single cells. The technology could be used to explore important questions in oncology, neuroscience, infectious diseases and agriculture. The technology would already be used in leading laboratories. Among them is the German Cancer Research Center (DKFZ).

"With its talented team and proprietary molecular mapping technology, Resolve is leading the new era of single-cell spatial analysis, opening the door to a wave of scientific discoveries that will redefine our understanding of disease and lead to new therapies and improved patient outcomes," said Laura Furmanski, partner and head of Patient Square Insights at Patient Square Capital.